Guanfacine 3 TAKEDA, guanfacine (as hydrochloride) 3 mg modified release tablet blister pack Australia - inglés - Department of Health (Therapeutic Goods Administration)

guanfacine 3 takeda, guanfacine (as hydrochloride) 3 mg modified release tablet blister pack

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 3.42 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid; indigo carmine aluminium lake; iron oxide yellow - indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants). must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Guanfacine 2 TAKEDA, guanfacine (as hydrochloride) 2 mg modified release tablet blister pack Australia - inglés - Department of Health (Therapeutic Goods Administration)

guanfacine 2 takeda, guanfacine (as hydrochloride) 2 mg modified release tablet blister pack

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 2.28 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants). must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

Guanfacine 1 TAKEDA, guanfacine (as hydrochloride) 1 mg modified release tablet blister pack Australia - inglés - Department of Health (Therapeutic Goods Administration)

guanfacine 1 takeda, guanfacine (as hydrochloride) 1 mg modified release tablet blister pack

takeda pharmaceuticals australia pty ltd - guanfacine hydrochloride, quantity: 1.14 mg - tablet, modified release - excipient ingredients: hypromellose; methacrylic acid - ethyl acrylate copolymer (1:1); sodium lauryl sulfate; polysorbate 80; microcrystalline cellulose; colloidal anhydrous silica; lactose; povidone; crospovidone; glycerol dibehenate; fumaric acid - indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6-17 years old, as monotherapy (when stimulants or atomoxetine are not suitable, not tolerated or have been shown to be ineffective) or as adjunctive therapy to psychostimulants (where there has been a sub-optimal response to psychostimulants). must be used as part of a comprehensive adhd management programme, typically including psychological, educational and social measures.

TAKHZYRO Israel - inglés - Ministry of Health

takhzyro

takeda israel ltd - lanadelumab - solution for injection - lanadelumab 150 mg/ml - lanadelumab - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (hae)in patients aged 2 years and older.

EDARBYCLOR TABLETS 40MG/12.5MG Singapur - inglés - HSA (Health Sciences Authority)

edarbyclor tablets 40mg/12.5mg

takeda pharmaceuticals (asia pacific) pte. ltd. - azilsartan medoxomil potassium 42.68mg eqv azilsartan medoxomil - tablet - 40mg

EDARBYCLOR TABLETS 40MG/25MG Singapur - inglés - HSA (Health Sciences Authority)

edarbyclor tablets 40mg/25mg

takeda pharmaceuticals (asia pacific) pte. ltd. - azilsartan medoxomil potassium 42.68mg eqv azilsartan medoxomil - tablet - 40mg

Vocinti 20mg Film-Coated Tablet Malasia - inglés - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

vocinti 20mg film-coated tablet

takeda malaysia sdn bhd - vonoprazan fumarate -

Vocinti 10mg Film-Coated Tablet Malasia - inglés - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

vocinti 10mg film-coated tablet

takeda malaysia sdn bhd - vonoprazan fumarate -

EDARBI TABLET 40MG Singapur - inglés - HSA (Health Sciences Authority)

edarbi tablet 40mg

takeda pharmaceuticals (asia pacific) pte. ltd. - azilsartan medoxomil potassium 42.68mg eqv azilsartan medoxomil - tablet - 40mg

EDARBI TABLET 80MG Singapur - inglés - HSA (Health Sciences Authority)

edarbi tablet 80mg

takeda pharmaceuticals (asia pacific) pte. ltd. - azilsartan medoxomil potassium 85.36mg eqv azilsartan medoxomil - tablet - 80mg